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i.org/1their possible associated intolerance and/or ineffectiveness in patients with high cardio-
vascular disease (CVD) risk initiating statins and/or ezetimibe. Patients aged ‡18 years who
initiated statins and/or ezetimibe from January 01, 2007, to June 30, 2011, were retro-
spectively identiﬁed from the IMS LifeLink PharMetrics Plus commercial claims database.
Patients were further classiﬁed into 2 cohorts: (1) history of cardiovascular event (CVE) and
(2) history of coronary heart disease risk equivalent (CHD RE). Patients had continuous
health plan enrollment ‡1 year pre- and post-index date (statin and/or ezetimibe initiation
date). Primary outcomes were index statin intensity, treatment modiﬁcations, possible
associated statin/nonstatin intolerance and/or ineffectiveness issues (based on treatment
modiﬁcation), and time-to-treatment modiﬁcations. Analyses for each cohort were stratiﬁed
by age group (<65 and ‡65 years). A total of 41,934 (history of CVE) and 170,344 patients
(history of CHD RE) were included. On the index date, 8.8% to 25.1% of patients were
initiated on high-intensity statin. Among patients aged <65, 79.2% and 48.8% of those with
history of CVE and 78.6% and 47.3% of those with a history of CHD RE had ‡1 and 2
treatment modiﬁcations, respectively. Among all patients, 24.6% to 25.6% had possible
statin intolerance and/or ineffectiveness issues after accounting for second treatment
modiﬁcation (if any). In conclusion, in patients with high CVD risk, index statin treatment
modiﬁcations that imply possible statin intolerance and/or ineffectiveness were frequent;
low use of high-intensity statins indicates unmet need in the management of hyperlipidemia
and possible remaining unaccounted CVD residual risk.  2016 The Authors. Published
by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/). (Am J Cardiol 2016;117:495e500)Despite the guidelines recommendation and efﬁcacy of
statins, not all patients, based on their cardiovascular risk, can
adequately control their low-density lipoprotein cholesterol
(LDL-C) on the starting statin dose; therefore, lipid-lowering
treatment (LLT) regimens may be modiﬁed. These modiﬁ-
cations may include dose escalation, switches to different
LLT agents, or augmentation with other LLTs.1 Some statin
treatment modiﬁcations may potentially be indicative of
index statin intolerance and/or ineffectiveness. There are no
standardized deﬁnitions or US Food and Drug Administration
diagnostic criteria for statin intolerance.2 Typically, it is
deﬁned as the inability to use statins because of signiﬁcant
symptoms (muscle myalgia and gastrointestinal side effects)
or elevated creatine kinase levels.2 Several national and in-
ternational medical societies recommend rechallenge of statinEconomics, Amgen Inc., Thousand Oaks, California;
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The American Heart Association (AHA)/American College
of Cardiology (ACC) 2013 guidelines indicate that therapy
ineffectiveness is a less-than-anticipated therapeutic response
to statin therapy in which upward titration of statin dose or
combination therapy is considered.3 Statin treatment intoler-
ance and/or ineffectiveness in patients with high risk could
potentially result in residual elevated risk for costly athero-
sclerotic cardiovascular disease (CVD) events. This study
examined LLT modiﬁcations in patients with high CVD
risk initiating statins and/or ezetimibe. This study also
investigated how such modiﬁcations may be associated
with possible treatment intolerance and/or ineffectiveness.
Methods
This was a retrospective cohort analysis using the IMS
LifeLink PharMetrics Plus commercial claims database from
January 1, 2006, to June 30, 2012. This nationally repre-
sentative, longitudinal database comprised managed care
health plan information throughout the United States, with
adjudicated claims of >150 million enrollees since 2006.8
Eligible patients aged 18 years with >1 outpatient
pharmacy claims for statins and/or ezetimibe from January
1, 2007, to June 30, 2011, from the IMS LifeLinkccess article
4.0/).
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Table 1
Deﬁnitions of treatment modiﬁcations
Treatment Modiﬁcation Deﬁnition
Dose escalation Continuation of index treatment with dose escalation of 25% between consecutive claims of statin
Dose reduction Continuation of index treatment with dose reduction of 25% between consecutive claims of statin
Augmentation Continuation of index treatment with addition of a new non-statin medication (or addition of a statin
medication for those with ezetimibe as index treatment)
Subtraction Moved from combination treatment to a subset of combination treatment/monotherapy within end of
days’ supply plus 60-day grace period
Switch to non-index
statin
Initiation of non-index statin post-index treatment date (Termination of index statin treatment was assumed
if days’ supply overlapped)
Switch to non-statin Initiation of non-statin post-index treatment date
Reinitiation Discontinuation of all components of index treatment and reinitiate index treatment after end of days’
supply plus 60-day grace period
Permanent discontinuation Discontinuation of all components of index treatment through end of follow-up period
496 The American Journal of Cardiology (www.ajconline.org)PharMetrics Plus Dataset were identiﬁed. The initiation date
of the ﬁrst statin and/or ezetimibe was designated as the
index date. The second outpatient pharmacy claim for sta-
tins and/or ezetimibe was required to be 6 months apart.
Two prescriptions were required as part of the inclusion
criteria to eliminate patients who received only 1 prescrip-
tion and never reﬁlled and, hence, would not have had a
possibility for a LLT modiﬁcation since initiation of ther-
apy. All patients were required to have continuous health
plan enrollment for 12 months pre-index date (baseline
period) and 12 months post-index date. The follow-up
period for treatment patterns varied in length from (and
including) the index date to the end of continuous health
plan eligibility or the end of the study period (June 30,
2012), whichever occurred ﬁrst. During this study period,
the National Cholesterol Education Program’s Adult Treat-
ment Panel III guidelines9 were the current treatment
guidelines and the AHA/ACC 2013 guidelines were not yet
adopted.
Patients with 1 outpatient pharmacy claim for statin
and/or ezetimibe in the 12 months before the ﬁrst index
statin and/or ezetimibe claim and those with medical claims
indicating pregnancy or delivery (International Classiﬁca-
tion of Diseases, Ninth Revision, Clinical Modiﬁcation
[ICD-9-CM] codes in Appendix A) at any time during the
baseline or follow-up period were excluded; patients with
>2 different index statins on the index date were excluded.
Patients were stratiﬁed into the following 2 high
CVD-risk cohorts:
1) History of cardiovascular event (CVE): Patients with
a history of CVEs, deﬁned as 1 nondiagnostic
medical claim (inpatient or outpatient) with a diag-
nosis or procedure code for myocardial infarction,
unstable angina, ischemic stroke, coronary artery
bypass graft surgery, percutaneous coronary inter-
vention, or transient ischemic attack (ICD-9-CM
codes in Appendix A) during the baseline period; and
2) History of coronary heart disease risk equivalent
(CHD RE): Patients with a history of CHD RE,
deﬁned as 1 nondiagnostic medical claim (inpatient
or outpatient) with a diagnosis or procedure code for
peripheral artery disease, abdominal aortic aneurysm,
ischemic heart disease, stable angina, or type 2diabetes mellitus (ICD-9-CM codes in Appendix A),
but no history of CVE during the baseline period.
Demographic and clinical characteristics of patients in
each cohort were examined. Initial statin intensity (low,
moderate, and high) was also recorded and stratiﬁed by
index year for each cohort. Using average daily dose, deﬁ-
nitions of different statin intensities were adapted from the
2013 ACC/AHA guidelines (Appendix B). The average
daily dose was deﬁned as the strength of the statin multi-
plied by the dose quantity and divided by the total days of
supply.
Treatment modiﬁcation (none, ﬁrst, and second) and time-
to-treatment modiﬁcation (days) during the follow-up period
were analyzed. Treatment modiﬁcations are deﬁned in
Table 1. Treatment modiﬁcations included dose escalation,
dose reduction, augmentation, subtraction for patients
receiving combination therapy, reinitiation of index therapy,
switching, and permanent LLT discontinuation. Using treat-
ment modiﬁcations observed in the claims data, statin dose
reduction, temporary discontinuation followed by reinitiation
of the same statin, and subtracting the statin from a combi-
nation therapy were considered as a signal for possible LLT
intolerance concerns. LLT ineffectiveness, used in this study,
was deﬁned in a similar way as the AHA/ACC 2013 guide-
lines (i.e., less-than-anticipated therapeutic response) and
treatment modiﬁcations, such as dose escalation and
augmentation with a non-statin LLT, were considered as
possible LLT ineffectiveness. To increase the likelihood that
the treatment modiﬁcations were associated with treatment
intolerance and/or ineffectiveness, we categorized and
accounted for both the observed ﬁrst and second treatment
modiﬁcations (if any) into possible LLT intolerance and/or
ineffectiveness issues (deﬁned in Appendix C). For example,
treatment modiﬁcations of switching to a different statin or
discontinuation of statin were categorized as possible statin
intolerance and/or ineffectiveness. Patients with no treatment
modiﬁcation, or those who had a ﬁrst treatment modiﬁcation
but no second treatment modiﬁcation, were classiﬁed into
low-/moderate-intensity statin and/or ezetimibe or high-
intensity statin treatment with/without ezetimibe treatment
depending on their statin intensity and/or ezetimibe treatment.
All measures, including patients’ demographic and clin-
ical characteristics, between the 2 cohorts were reported.
Table 2
Baseline demographic and clinical characteristics of high-risk cardiovascular disease patients
Variable History of CVE
(N¼41,934)
History of CHD RE
(N¼170,344)
Age (Mean and SD) (Years) 57.6 (10.2) 56.6 (10.8)
Age by Medicare Category (Years)
<65 34674 (82.7) 140372 (82.4)
65 7260 (17.3) 29972 (17.6)
Gender
Male 28113 (67.0%) 97559 (57.3%)
Geographic Distribution
Northeast 12780 (30.5%) 54310 (31.9%)
North Central 9003 (21.5%) 42990 (25.2%)
West 16987 (40.5%) 53242 (31.3%)
South 3164 (7.5%) 19802 (11.6%)
Payer Type
Health Maintenance Organizations 5764 (13.7%) 29489 (17.3%)
Indemnity 2547 (6.1%) 11019 (6.5%)
Preferred Provider Organizations 30014 (71.6%) 106923 (62.8%)
Point of Service 3441 (8.2%) 22027 (12.9%)
Consumer-directed Health Care 33 (0.1%) 585 (0.3%)
Unknown/Missing 135 (0.3) 301 (0.2%)
Baseline Deyo-Charlson Comorbidity Index Categories
Mean (SD) 1.9 (1.7%) 1.5 (1.3%)
0 5714 (13.6%) 23429 (13.8%)
1 16813 (40.1%) 96934 (56.9%)
2 9083 (21.7%) 21149 (12.4%)
3 10324 (24.6%) 28832 (16.9%)
Baseline Comorbidities
Hyperlipidemia 30309 (72.3%) 133091 (78.1%)
Hypertension 30017 (71.6%) 116933 (68.6%)
Arrhythmias 11559 (27.6%) 14118 (8.3%)
Diabetes (Type 1 or 2) 9907 (23.6%) 127234 (74.7%)
Chronic Respiratory Disease 7624 (18.2%) 20685 (12.1%)
Carotid Artery Disease 5707 (13.6%) 4612 (2.7%)
Obesity 5355 (12.8%) 17629 (10.3%)
Congestive Heart Failure 5096 (12.2%) 5818 (3.4%)
Peripheral Arterial Disease 4522 (10.8%) 15686 (9.2%)
Myalgia/muscle weakness 3189 (7.6%) 8475 (5.0%)
Cancer (excluding non-melanoma skin cancer) 2515 (6.0%) 10065 (5.9%)
Liver Disease 901 (2.1%) 4424 (2.6%)
Hemorrhagic Stroke 697 (1.7%) 221 (0.1%)
Metabolic Syndrome 512 (1.2%) 3025 (1.8%)
End-stage Renal Disease 403 (1.0%) 1115 (0.7%)
Baseline Concomitant Medications
Anti-hypertensive Medications 23156 (55.2%) 102604 (60.2%)
Oral Antidiabetic Medications 4717 (11.2%) 71416 (41.9%)
Insulin 1639 (3.9%) 16143 (9.5%)
CHD RE ¼ coronary heart disease risk equivalent; CVE ¼ cardiovascular event; SD ¼ standard deviation.
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and 65 years) to investigate the impact (if any) of Medi-
care eligibility.Results
After applying inclusion and exclusion criteria, 41,934
patients had a history of CVE and 170,344 had a history of
CHD RE during the baseline period (Appendix D).
The average ages of patients with a history of CVE and
history of CHD RE were 58 and 57 years, respectively
(Table 2). The mean (SD) Deyo-Charlson Comorbidity
Index score for patients in the history of CVE cohort was 1.9(1.7) and was 1.5 (1.3) for patients in the history of
CHD RE cohort (Table 2). Study results for those aged <65
years are reported subsequently; similar patterns were also
observed for patients aged 65 years.
In both cohorts, from 2007 to 2011, in patients aged
<65 years, 6.7% to 20.9% initiated a low-intensity statin,
66.6% to 77.8% initiated a moderate-intensity statin, and
8.8% to 25.1% initiated a high-intensity statin.
Figure 1 shows the percentage of patients with an initial
treatment modiﬁcation or no modiﬁcation for both cohorts,
among patients aged <65 years. Of those, 79.2% and 78.6%
in the history of CVE and history of CHD RE cohorts,
respectively, had at least 1 treatment modiﬁcation. In the
Figure 1. First treatment modiﬁcation among high CVD risk cohorts (aged <65 years).
Figure 2. Statin treatment intensity and possible LLT intolerance and/or ineffectiveness issues among high CVD risk cohorts (aged <65 years) with and without
treatment modiﬁcations. Note: colors denoting different categories used in Figure 2 correspond to those in Appendix C.
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same top 2 most common treatment modiﬁcations as those
aged <65 years. In the history of CHD RE cohort, the top 3
most common treatment modiﬁcations were the same for
patients aged <65 and 65 years. Treatment trends among
patients aged 65 years are available in Appendix E.
The average number of days to the ﬁrst treatment
modiﬁcation among patients in both cohorts ranged from
130 to 399 days. In both cohorts, the average time-to-
reinitiation was the longest (>1 year), whereas time-to-
augmentation (<5 months) was the shortest.
In the history of CVE and CHD RE cohorts, 48.8% and
47.3%, respectively, of patients aged <65 years had at least
a second treatment modiﬁcation. Of those, reinitiation was
the most common second treatment modiﬁcation (history of
CVE: 11.5%, history of CHD RE: 14.8%). The average
number of days from the index date to the second treatmentmodiﬁcation across the 2 cohorts ranged from 367 to
610 days.
Among patients aged <65 years, 27.1% of the history of
CVE cohort and 28.5% of the history of CHD RE cohort
were classiﬁed as having possible statin intolerance
(Figure 2). In addition, among patients aged 65 years,
23.9% of the history of CVE cohort and 23.8% of the his-
tory of CHD RE cohort were associated with possible statin
intolerance (Appendix F).
Discussion
This is one of the ﬁrst studies to use a real-world,
retrospective claims-based analysis to associate observed
LLT modiﬁcations, if any, with possible treatment intoler-
ance and/or ineffectiveness in patients with high CVD risk.
Previous studies of statin intolerance have been largely
Coronary Artery Disease/Lipid-Lowering Treatment Patterns 499conﬁned to randomized clinical trials, which have led to
systemic underestimation of statin intolerance because of the
selective inclusion criteria. Our study showed that >75% of
patients initiating statin and/or ezetimibe treatment had at
least 1 treatment modiﬁcation and >45% had at least 2
treatment modiﬁcations, implying that many patients initi-
ating statins and/or ezetimibe experienced issues with their
index and ﬁrst treatment modiﬁcation during the study
period. As deﬁned and categorized in our study, these
treatment modiﬁcations are associated with >23% of pa-
tients having possible statin intolerance and/or ineffective-
ness issues after accounting for the second treatment
modiﬁcation, if any.
The ACC/AHA guidelines generally recommend the
need for high-intensity statin treatment for patients with
atherosclerotic CVD.3 Although patients with CVD repre-
sent a high-risk group, in our study, <26% of the CVD
cohort were prescribed high-intensity index statins from
2007 to 2011. The low initiation rate of high-intensity sta-
tins among the high CVD risk cohorts suggests the need for
better LLT management within this patient population.
Additional research should use contemporary data to further
understand the effects of the introduction of current
guidelines.
Our study showed that 21% to 24% of patients with high
CVD risk permanently discontinued all LLTs during the
follow-up period. In a retrospective study conducted by
Caspard et al, 26% of patients discontinued treatment during
the ﬁrst year, and the probability of resuming statin treat-
ment was 51% within 2 years after the last prescription ﬁll.10
Simpson et al11 reported 46.9% of the patients in their study
discontinued LLT 3 months after drug initiation during the
12-month follow-up period. Although the discontinuation
rates vary among these studies, primarily because of the
varying deﬁnitions of discontinuation and follow-up pe-
riods, these studies corroborate with other published studies
that discontinuation was common among statin users.12e14
For some patients, adverse events associated with statin
use (e.g., musculoskeletal issues, peripheral neuropathy,
insomnia, creatine phosphokinase, and liver function test
elevation) inﬂuence therapy decisions, thereby increasing
the likelihood of statin therapy discontinuation.3,15e17 In a
recent survey of self-reported former and current statin
users, nearly 2/3 of patients (62%) who discontinued statin
use did so because of side effects, most commonly muscle
related.18 Also, among current statin users who switched
treatment, 28% said they switched because of side effects
and 22% switched because of the lack of efﬁcacy. These
results suggest that treatment modiﬁcations may be associ-
ated with possible statin intolerance and/or ineffectiveness.
Patient registries, along with observational studies, showed
a 7% to 29% prevalence of statin intolerance.12,13,17e20 The
reported statin intolerance varied depending on how intol-
erance was assessed and the setting. After accounting for the
second treatment modiﬁcation (if any), our study showed
that 24% to 29% of patients were associated with possible
statin intolerance. Differences between previous studies and
our study may be attributed to a number of factors, including
statin intensity prescribed (high intensity vs any intensity),17
differences in patient selection (general population vs
hyperlipidemic patients),20 and differences in possible statinintolerance identiﬁcation (patient reported vs observed
treatment modiﬁcation).18
Previous studies of statin treatment patterns have focused
on monotherapy, adherence, or post-therapeutic sub-
stitution.21e23 Simpson et al11 concluded that patients with
high CVD risk usually initiated moderate-intensity statins,
which was similar to our ﬁndings, but, unlike our study,
which included combination treatment, Simpson’s study
was based on initiation of statin monotherapy. Parker et al19
examined the effects of statins on skeletal muscle function
and documented that atorvastatin signiﬁcantly increased the
frequency of myalgia, but unlike our study, this was a
randomly assigned double-blind clinical trial that only
examined the effect of 1 statin among healthy subjects.
Harley et al23 followed patients after they switched from
simvastatin to other statins or a combination of simvastatin
and ezetimibe and found that most patients switching from
higher doses of simvastatin switched to a ﬁxed-dose com-
bination of simvastatin plus ezetimibe. However, none of
these studies have put treatment modiﬁcations into
perspective by critically analyzing and providing detailed
classiﬁcation of treatment modiﬁcation and possible asso-
ciated statin intolerance and/or ineffectiveness issues.
To our knowledge, there is currently no existing, validated
claims-based algorithm to identify stain intolerance and/or
ineffectiveness issues. Nevertheless, statin intolerance man-
agement, based on LLT modiﬁcations, have been mentioned
in national and international guidelines.3e6 The National
Lipid Association deﬁnes statin intolerance as a clinical
syndrome characterized by the inability of a patient to tolerate
statin therapy with a statin challenge of2 different statins.24
For patients showing symptoms of statin intolerance, the
ACC/AHA,3 European Atherosclerosis Society,4 and Cana-
dian Working Group Consensus6 recommend LLT modiﬁ-
cation (e.g., rechallenge, dose reduction, switching to another
LLT). Based on these guideline deﬁnitions/recommenda-
tions, the present study used treatment modiﬁcations (e.g.,
dose reduction, reinitiation) to connote possible statin intol-
erance and ineffectiveness. Our claims-based analyses pre-
cluded us from providing deﬁnite reasons regarding
treatment modiﬁcations or determining the cause of possible
statin intolerance. However, while accounting for up to 2
treatment modiﬁcations, our study results were indicative of
possible associated statin intolerance and/or ineffectiveness
in patients with high CVD risk. Possible treatment ineffec-
tiveness for the present study included dose escalation and
augmentation, which may have been because of low or
moderate statin dose initiation; however, data were not
available on the exact reason for treatment change. Treatment
modiﬁcations may also be because of unobserved health
system changes (e.g., change in health plan formulary
coverage). Further research (e.g., clinical chart review) is
warranted to conﬁrm our ﬁndings and explore causal links
between statin intolerance and/or ineffectiveness with spe-
ciﬁc LLTmodiﬁcations to provide more deﬁnite conclusions.
Additional study limitations include potential coding,
billing, and recording errors from the use of claims data. The
dispensed LLT prescription claims do not guarantee that
patients actually took their medications as prescribed. The
requirement for commercially insured patients with contin-
uous medical and pharmacy coverage for 12 months before
500 The American Journal of Cardiology (www.ajconline.org)and after the index date may have resulted in selection bias
by eliminating patients who had <24 months of data.
Therefore, the results of this study may not be generalizable
to other patient populations, including uninsured pop-
ulations. Speciﬁc LDL-C levels data were not available in
the data set to assess their impact on treatment modiﬁca-
tions. Some treatment modiﬁcations may be indicative of
patients achieving LDL-C targets, but this may represent a
small proportion of patients; as reported by the US Centers
for Disease Control and Prevention, fewer than 1 of every 3
adults have their LDL-C under control (at target levels).25
Nonetheless, previous studies that used speciﬁc LDL
levels are limited in size or generalizability.10,26
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